How much does RYZNEUTA (Efbemalenograstim Alfa Injection) Cost& price without insurance in China?
RYZNEUTA® is the commercial brand name of Efbemalenograstim Alfa Injection, a long-acting recombinant human granulocyte colony-stimulating factor (rhG-CSF) analog developed by Yisheng Biopharma. It stimulates the proliferation and differentiation of neutrophil progenitor cells in the bone marrow, thereby increasing peripheral blood neutrophil counts.
Main Indications
Reduction of the incidence of febrile neutropenia in adult patients with non-myeloid malignancies receiving myelosuppressive anticancer chemotherapy associated with a clinically significant incidence of febrile neutropenia.
Common Side Effects
Common mild adverse reactions: Bone pain, myalgia, arthralgia, fatigue, headache, and nausea.
Laboratory abnormalities: Transient elevations in lactate dehydrogenase (LDH), alkaline phosphatase (ALP), and uric acid.
Severe but uncommon risks: Severe allergic reactions (including anaphylaxis), splenic rupture, acute respiratory distress syndrome (ARDS), and sickle cell crises in patients with sickle cell disease.
Approval Status in China
RYZNEUTA® (Efbemalenograstim Alfa Injection, 20mg/1.0mL) was officially approved for marketing in China in 2023. It is currently a prescription supportive care drug for chemotherapy-induced neutropenia.
Buy RYZNEUTA (Efbemalenograstim Alfa Injection) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
